Quantity of eligible patients: CDEC discussed the uncertainty in the number of patients with reasonably intense to severe hemophilia B in Canada suitable for etranacogene dezaparvovec. Scientific industry experts consulted by CADTH indicated that some clients that are categorized as possessing mild